Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5788-5796

  Ryan, Sean O ^a   Turner, Michael S ^a   Gariépy, Jean ^b   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Sunnybrook Health Sciences Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; EPITOPE; GLYCOPEPTIDE; MUCIN 1; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG RESPONSE; EMBRYO; FEMALE; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VARIABLE NUMBER OF TANDEM REPEAT; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUCIN-1;

EID: 77955018971     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4519     Document Type: Article

References (50)

1. Ryan SO, Gantt KR, Finn OJ. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol 2007; 142:179-89.
2. + T-cell repertoire. Cancer Res 2005;65:6443-9.
3. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 2007; 179:993-1003.
4. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 1998;161:5500-6.
5. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
6. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004; 82:249-93.
7. Jerome KR, Barnd DL, Bendt KM, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
8. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 1993;151:1654-62.
9. Lepisto AJ, Moser AJ, Zeh H, et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 2008;6:955-64.
10. Ramanathan RK, Lee KM, McKolanis J, et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 2005;54:254-64.
11. Beatty PL, Plevy SE, Sepulveda AR, Finn OJ. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J Immunol 2007;179:735-9.
12. Rowse GJ, Tempero RM, VanLith ML, Hollingsworth MA, Gendler SJ. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res 1998;58:315-21.
13. Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 2007;178:2787-93.
14. Gerloni M, Castiglioni P, Zanetti M. The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice. J Immunol 2005;175:6551-9.
15. Ding C, Wang L, Marroquin J, Yan J. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1. Blood 2008;112: 2817-25.
16. + T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-44.
17. Vlad AM, Finn OJ. Glycoprotein tumor antigens for immunotherapy of breast cancer. Breast Dis 2004;20:73-9.
18. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med 1997;75:594-602.
19. Ninkovic T, Kinarsky L, Engelmann K, et al. Identification of Oglycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 2009;47: 131-40.
20. Vlad AM, Muller S, Cudic M, et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002;196:1435-46.
21. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005;83:440-8.
22. Ryan SO, Vlad AM, Islam K, Gariépy J, Finn OJ. Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice. Biol Chem 2009;390:611-8.
23. Broeren CP, Verjans GM, Van Eden W, Kusters JG, Lenstra JA, Logtenberg T. Conserved nucleotide sequences at the 5′ end of T cell receptor variable genes facilitate polymerase chain reaction amplification. Eur J Immunol 1991;21:569-75.
24. Kouskoff V, Signorelli K, Benoist C, Mathis D. Cassette vectors directing expression of T cell receptor genes in transgenic mice. J Immunol Methods 1995;180:273-80.
25. Letourneur F, Malissen B. Derivation of a T cell hybridoma variant deprived of functional T cell receptor α and β chain transcripts reveals a nonfunctional α-mRNA of BW5147 origin. Eur J Immunol 1989;19:2269-74.
26. Allman D, Sambandam A, Kim S, et al. Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 2003;4:168-74.
27. Brokx RD, Revers L, Zhang Q, et al. Nuclear magnetic resonance-based dissection of a glycosyltransferase specificity for the mucin MUC1 tandem repeat. Biochemistry 2003;42:13817-25.
28. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001;166:6555-63.
29. + T cells. Cancer Res 1998;58:5066-70.
30. + regulatory T cell induction and expansion. J Immunol 2009;183:4895-903.
31. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007;123:18-29.
32. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998;76:34-40.
33. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987;49:273-80.
34. + regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2:301-6.
35. + regulatory T cells. J Immunol 2009;182:6736-43.
36. Cloosen S, Arnold J, Thio M, Bos GMJ, Kyewski B, Germeraad WTV. Expression of tumor-associated differentiation antigens, MUC1 glycoforms and CEA, in human thymic epithelial cells: implications for self-tolerance and tumor therapy. Cancer Res 2007;67: 3919-26.
37. Tykocinski L-O, Sinemus A, Kyewski B. The thymus medulla slowly yields its secrets. Ann N Y Acad Sci 2008;1143:105-22.
38. Hiltbold EM, Vlad AM, Ciborowski P, Watkins SC, Finn OJ. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J Immunol 2000;165:3730-41.
39. Fletcher AL, Lukacs-Kornek V, Reynoso ED, et al. Lymph node fibroblastic reticular cells directly present peripheral tissue antigen under steady-state and inflammatory conditions. J Exp Med 2010;207: 689-97.
40. Bos R, van Duikeren S, Morreau H, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008;68:8446-55.
41. Barratt-Boyes SM, Vlad A, Finn OJ. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 1999;5: 1918-24.
42. Gardner JM, DeVoss JJ, Friedman RS, et al. Deletional tolerance mediated by extrathymic Aire-expressing cells. Science 2008;321: 843-7.
43. Cohen JN, Guidi CJ, Tewalt EF, et al. Lymph node-resident lymphatic endothelial cells mediate peripheral tolerance via Aire-independent direct antigen presentation. J Exp Med 2010;207:681-8.
44. Steinman RM, Hawiger D, Liu K, et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003;987:15-25.
45. Parish IA, Heath WR. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol Cell Biol 2008;86: 146-52.
46. Engelhard VH, Altrich-Vanlith M, Ostankovitch M, Zarling AL. Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 2006;18:92-7.
47. Ju T, Cummings RD. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 2005;437:1252.
48. Bäcklund J, Carlsen S, Höger T, et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci 2002;99:9960-5.
49. Hanisch F-G. O-Glycosylation of the mucin type. Biol Chem 2001; 382:143-9.
50. Schietinger A, Philip M, Yoshida BA, et al. A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science 2006;314:304-8.